Loading
A phase 2 trial of izalontamab brengitecan and glecirasib in lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., not yet recruiting.
A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer is a phase 2, interventional study registered as NCT07827261 by Sichuan Baili Pharmaceutical Co., Ltd., with a registry enrolment figure of 36 participants, started 2026-09 and due to reach its primary completion in 2028-12. Interventions recorded: BL-B01D1; Glecirasib. Conditions listed: Non-small Cell Lung Cancer. Primary outcome: Objective Response Rate (ORR). Lung eligibility wording from the registry: "Patients with locally advanced or metastatic non-small cell lung cancer;". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares KRAS G12C-mutant non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares KRAS G12C-mutant non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares SystImmune / Sichuan Biokin, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/